510
Participants
Start Date
August 15, 2018
Primary Completion Date
November 30, 2022
Study Completion Date
November 30, 2024
Crenolanib
Crenolanib will be administered orally
Midostaurin
Midostaurin will be administered orally
Cytarabine
100 mg/m² IV continuous infusion over 24 hours
Duanorubicin
90 mg/m2 IV
RECRUITING
New York University, New York
RECRUITING
Columbia University, New York
RECRUITING
Cornell University, New York
RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Roswell PArk, Buffalo
RECRUITING
University of Rochester Medical Center, New York
RECRUITING
University of Virginia Health System, Charlottesville
RECRUITING
Wake Forest Baptist Health, Section on Hematology & Oncology, Winston-Salem
RECRUITING
The UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Rush Medical Center, Chicago
RECRUITING
University of Illinois at Chicago, Chicago
RECRUITING
University of Chicago, Chicago
RECRUITING
University of Kansas, Kansas City
RECRUITING
Ronald Reagan UCLA Medical Center, Los Angeles
RECRUITING
City of Hope National Medical Center, Duarte
RECRUITING
US Davis Health, Sacramento
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
Indiana University, Indianapolis
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Beth Israel Deacnss Medical Center Oncology, Boston
RECRUITING
Dana-Farber Cancer Insitute, Boston
RECRUITING
John Theurer Cancer Center at Hackensack UMC, Hackensack
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
RECRUITING
Mount Sinai, New York
Lead Sponsor
Arog Pharmaceuticals, Inc.
INDUSTRY